TWST:NASDAQTwist Bioscience Corporation Analysis

Twist Bioscience is trading at $74.05, well above its 20‑day ($63.74), 50‑day ($59.26) and 200‑day ($41.80) SMAs, signaling strong bullish momentum. The RSI sits at 65.9, still below the overbought threshold, and the MACD line remains bullish with a positive histogram, reinforcing the upward trend. However, the stock exhibits extreme volatility (71% 30‑day) and a high beta of 2.5, indicating sensitivity to market swings. Fundamentally, the company posted 19% revenue growth and a solid 52% gross margin, yet operating margins are deeply negative (‑34.9%) and cash flow remains in the red, with a debt‑to‑equity of 24.4. Valuation metrics are stretched – a price‑to‑book of 10.1 and price‑to‑sales of 11.3 far exceed peers, and the current price is above the median analyst target of $65.5, suggesting overvaluation. Recent news of the “Complex Genes” launch adds a growth catalyst, but insider sales and ongoing cash burn temper enthusiasm.